NSCLC Isotoxic Hypofractionated Chemoradiotherapy (IHRC)
Carcinoma, Non-Small-Cell Lung

About this trial
This is an interventional treatment trial for Carcinoma, Non-Small-Cell Lung focused on measuring isotoxic, hypofractionated radiotherapy, Non-Small-Cell Lung
Eligibility Criteria
Inclusion Criteria:
- Pathological or cytological diagnosis of non-small cell lung cancer patients, the clinical stage using the eighth edition of American Joint Committee on Cancer(AJCC), including stage III without resectable or who when SBRT/SABR are not suitable;
- Age ≥ 18 years,≤ 75 years;
- The expected survival period is ≥ 3 months;
- Karnofsky performance status (KPS) score ≥ 60;
- Normal blood account , liver and kidney function;
- Forced expiratory volume in 1 second of 0.75 L or greater.
Exclusion Criteria:
- Serious medical problems require hospitalization, include (but not limited to ): history of pulmonary fibrosis, previous myocardial infarction within 6 months, heart failure grade II and above, uncontrolled heart failure, uncontrolled chronic obstructive pulmonary disease (COPD), uncontrolled diabetes .et al;
- Esophageal invasion (cT4);
- Others are not suitable for receiving radiotherapy and chemotherapy.
Sites / Locations
- The Second Hospital of Hebei Medical UniversityRecruiting
Arms of the Study
Arm 1
Experimental
isotoxic hypofractionated group
Hypofractionated radiation: 1. Split mode: 3Gy/f. 2,Individualized prescriptions for different patients: (1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 69Gy 3. Maximum limit: If the limit of any "A" is not reached, the maximum radiation dose is 69 Gy. The lowest radiation dose: 45Gy. Chemotherapy: Platinum-containing two-drug regimen: docetaxel + lobaplatin: Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1; repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy. The same chemotherapy regimen is used up to 4 cycles as consolidation after the completion of radiotherapy.